Review: orlistat and sibutramine are modestly effective for weight loss at 1 year

doi:10.1136/ebm.10.1.13

HOME

Author	Keyword(s)
Vol	Page
[Advanced]

This Article

	Full Text
	Full Text (PDF)
	Submit a response
	Alert me when this article is cited
	Alert me when eLetters are posted
	Alert me if a correction is posted

Services

	Email this article to a friend
	Similar articles in this journal
	Add article to my folders
	Download to citation manager
	Request Permissions

Citing Articles

	Citing Articles via Google Scholar

Google Scholar

	Articles by Byrne, C. D
	Articles by Wild, S.
	Search for Related Content

PubMed

	Articles by Byrne, C. D
	Articles by Wild, S.

Evidence-Based Medicine 2005; 10:13
© 2005 BMJ Publishing Group Ltd.

Therapeutics

Review: orlistat and sibutramine are modestly effective for weight loss at 1 year

Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev 2004;(3):CD004094.

Q What is the effectiveness of anti-obesity medications in trials with $>=$ 1 year follow up?

Clinical impact ratings GP/FP/Primary care $*$ $*$ $*$ $*$ $*$ $*$ ${star}$ IM/Ambulatory care $*$ $*$ $*$ $*$ $*$ ${star}$ ${star}$ Endocrine $*$ $*$ $*$ $*$ $*$ $*$ ${star}$

Key Words: weight loss • anti obesity agents • appetite depressants • lactones

The first 150 words of the full text of this article appear below.

METHODS
Data sources: Medline (1966 to December 2002), EMBASE/Excerpta Medica (1980to December 2002), Cochrane Controlled Trials Register (Issue3, 2002), Current Controlled Trials metaRegister of Controlledtrials (December 2002), bibliographies of relevant studies,and experts and manufacturers.

Study selection and assessment: randomised controlled trials (RCTs) of approved anti-obesityagents for weight loss or weight maintenance in adults withbody mass index (BMI) $>=$ 30 kg/m² or $>=$ 27 kg/m² plus $>=$ 1 obesity relatedcomorbid condition (eg, coronary artery disease, stroke, type2 diabetes, heart failure, dyslipidaemia, hypertension, reproductiveor gastrointestinal cancer, gallstones, fatty liver disease,osteoarthritis, and sleep apnoea), had blinding of patientsand healthcare providers, included a placebo group or anotheranti-obesity drug group, used an intention to treat analysis,and had $>=$ 1 year of follow up. Studies of off-label therapy; drugswith high addiction potential that preclude long term use; orinvestigational, herbal, or alternative compounds were excluded.Study quality . . . [Full text of this article]

Christopher D Byrne, FRCP, FRCPath, PhD¹, Sarah Wild, MRCP, MRCGP, MFPHM, PhD²

¹ Southampton General Hospital
Southampton, UK
² University of Edinburgh
Edinburgh, UK